

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: **Frank Grosveld**

Confirmation No.: **1498**

Serial No.: **10/693,308**

Group Art Unit: **1621**

Filing Date: **October 24, 2003**

Examiner: **Anoop K. Singh**

For: **IMMUNOGLOBULIN 2**

Customer No.: **34132**

EXPRESS MAIL LABEL NO: EV513558352US
DATE OF DEPOSIT: October 19, 2006

MAIL STOP AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56 and in accordance with 37 C.F.R. §§ 1.97 and 1.98, information relating to the above-identified application is hereby disclosed, the Examiner in charge of the above-identified application is requested to consider and make of record the references listed on the PTO Forms SB/08A and SB/08B, formerly known as PTO Form 1449 submitted herewith.

Inclusion of the information submitted herewith is not to be construed as an admission that the information is material as that term is defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made.

This Supplemental Information Disclosure Statement is being filed:

- ☐ within three months of the filing date of the patent application.
- ☐ within three months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 of the international application.
- ☐ **before** the mailing date of a first Office Action on the merits.

☒ after the mailing date of a first Office Action on the merits, but before the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, and accordingly is accompanied by:

☐ the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below);

or

☒ the Fee of \$180.00 set forth in 37 C.F.R. § 1.17(p); or

☐ No fee is owed by the applicant(s).

☐ In accordance with 37 C.F.R. § 1.129(a), this Supplemental Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below) and the fee of \$180.00 as set forth in 37 C.F.R. § 1.17(p), is attached.

☐ after the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, but before the payment of the Issue Fee, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e), (see "Statement," and "Fees" below).

☒ Copies of the references listed on the attached PTO Forms SB/08a and SB/08b, formerly known as PTO Form 1449 are enclosed.

EXCEPT THAT:

☐ In view of the voluminous nature of reference ____, and the likelihood that this reference is available to the Examiner, a copy is not enclosed herewith.

☐ In accordance with 37 C.F.R. § 1.98(d), copies of the following references listed on the attached PTO Form SB/08A and PTO Form SB/08B, formerly known as PTO Form 1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application.

- ☐ If the foregoing publication is not available to the Examiner, Applicant will endeavor to supply a copy at the Examiner's request.

Statement under 37 C.F.R. § 1.97(e)

- ☐ The undersigned attorney hereby states that each item information contained in the Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Supplemental Information Disclosure Statement.


Fees

- ☐ No Fee is owed by the applicant(s).
- ☒ The Supplemental Information Disclosure Statement Fee of \$180.00 under 37 C.F.R. § 1.17(p) is enclosed herewith.

Method of Payment of Fees


- ☐ Attached is a check in the amount of \$_____. This form is submitted in duplicate.
- ☒ Charge Deposit Account No. 50-1275 in the amount of \$180.00. This form is submitted in duplicate.
- ☒ Please charge any deficiency or credit any overpayment to Deposit Account 50-1275.
- ☐ No fee or Statement is required under 37 C.F.R. § 1.97(b).

Respectfully submitted,


Doreen Yatko Trujillo
Registration No. 35,719

Dated: October 19, 2006

COZEN O'CONNOR, P.C.
1900 Market Street, 5th Floor
Philadelphia, PA 19103-3508
(215) 665-5593 - Telephone
(215) 665-2005 - Facsimile



Approved for use through 09/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

(Use as many sheets as necessary)

| | | | |
|-------|---|----|---|
| Sheet | 1 | of | 2 |
|-------|---|----|---|

Complete if Known

| | |
|-------------------------------|------------------|
| <i>Application Number</i> | 10/693,308 |
| <i>Filing Date</i> | October 24, 2003 |
| <i>First Named Inventor</i> | Grosveld |
| <i>Art Unit</i> | 1632 |
| <i>Examiner Name</i> | Singh |
| <i>Attorney Docket Number</i> | CARP0015-100 |


[illegible][illegible]

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Subsidiary Form 949B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

| | |
|------------------------|------------------|
| Application Number | 10/693,308 |
| Filing Date | October 24, 2003 |
| First Named Inventor | Grosveld |
| Art Unit | 1632 |
| Examiner Name | Singh |
| Attorney Docket Number | CARP0015-100 |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|---------------------|-----------------------|---|----------------|
| | I | DAVIES AND RIECHMANN, "Antibody VH Domains as Small Recognition Units," Biotechnology, 1995, v. 13, 475-479 | |
| | J | DAVIES AND RIECHMANN, "Affinity improvement of single antibody VH domains: residues in all three hypervariable regions affect antigen binding," Immunotechnology 2, 1996, 169-179 | |
| | K | GROSVELD ET AL, "Position-Independent, High-Level Expression of the Human [Beta]-Globin Gene in Transgenic Mice, Cell, December 24, 1987, v. 51, 975-985 | |
| | L | JANSSES ET AL, "Generation of heavy-chain-only antibodies in mice," PNAS, October 10, 2006, v. 103, no. 41, 15130-15135 and supplementary material on-line | |
| | M | LI ET AL, "Locus Control Regions coming of age at a decade plus," TIG, October 1999, v. 15, no. 10, 403-408 | |
| | N | SITIA ET AL, "Developmental Regulation of IgM Secretion: The Role of the Carboxy-Terminal Cysteine," Cell, March 9, 1990, v. 60, 781-790 | |
| | O | SPINELLI ET AL, "The crystal structure of a llama heavy chain variable domain," Nature Structural Biology, September, 1996, v. 3, no. 9, 752-757 | |
| | P | WARD ET AL, "Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli," Nature, October 12, 1989, v. 341, 544-546 | |
| | | | |
| | | | |
| | | | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.